The increased sensitivity to these drugs in tumor cells with either somatic or germline BRCA1 mutations suggests that the mechanism of HRD does not depend on whether the BRCA1 mutation was inherited, or arose during the life of the patient. The gene discussed is BRCA1; the disease is neoplasm.